Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020

Article information

Cancer Res Treat. 2023;55(2):385-399
Publication date (electronic) : 2023 March 10
doi : https://doi.org/10.4143/crt.2023.447
1Korea Central Cancer Registry, National Cancer Center, Goyang, Korea
2Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea
3National Cancer Control Institute, National Cancer Center, Goyang, Korea
4National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
Correspondence: Kyu-Won Jung, Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea, Tel: 82-31-920-2015, Fax: 82-31-920-2179, E-mail: ara@ncc.re.kr
*Regional Cancer Registry CommitteeChang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Cancer Registry, Ulsan University Hospital), Yong-Dae Kim (Chungbuk Cancer Registry, Chungbuk National University Hospital), Young-Taek Kim (Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital), Chul Min Park (Jeju Cancer Registry, Jeju National University and Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Jeonbuk National University Hospital), Kyu-Hyoung Lim (Kangwon Cancer Registry, Kangwon National University and Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University), Sun-Seog Kweon (Gwangju/Jeonnam Cancer Registry, Chonnam National University Hwasun Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Ki-Soo Park (Gyeongnam Cancer Registry, Gyeongsang National University and Hospital).
Received 2023 March 08; Accepted 2023 March 10.

Abstract

Purpose

The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.

Materials and Methods

Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.

Results

The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.

Conclusion

In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.

Introduction

Cancer is one of the leading causes of death worldwide, with an estimated 19.3 million new cancer cases and 10 million deaths worldwide in 2020 [1]. In Korea, cancer has been the leading cause of death since 1983 [2]. In response to this public health threat, the National Plan for Cancer Control was implemented in 1996, and the 4th stage is in effect from 2021. As a fundamental part of the Plan, the Korea Central Cancer Registry (KCCR) publishes cancer registration statistics every year. In 2020, there was a negative impact on cancer diagnosis and treatment as medical use declined due to the coronavirus disease 2019 (COVID-19) pandemic. Reduced and delayed access to health care, including dec-reased cancer screening rates, was a phenomenon that has appeared not only in Korea but globally [35]. While short-term decreases in cancer incidence statistics are expected, it will take years to quantify the associations and consequences of these phenomenon, which is beyond the scope of this article [3]. In this study, we report the most recent nationwide statistics on cancer incidence, survival, prevalence, and mortality, and their temporal trends.

Materials and Methods

1. Data sources

Annual cancer statistics in Korea are calculated using a national and population-based database of cancer occurrence, the Korea National Cancer Incidence Database (KNCI DB). Every year, the KCCR collects information on patients diagnosed with cancer at hospitals across the country during the past year. The data from previous year is backed up with information compiled by central and 11 regional cancer registries, including information on cancer patients missed in hospital-based registrations. Hence, it takes two years to complete and calculate the year’s KNCI DB and cancer statistics. The KCCR has reported nationwide statistics since 1999; other detailed information on the KCCR and KNCI DB is provided in our previous report [6]. Completeness is an important indicator of data quality, and the 2020 KNCI DB was estimated to be 98.3% complete using the method proposed by Ajiki et al. [7].

Annual mid-year population data and recently updated mortality data including causes of death from 1983 were obtained from Statistics Korea [2]. To confirm the validity of individual vital statuses used in survival and prevalence calculation, the KNCI DB was linked to both mortality and population resident registration data, which were obtained from the Ministry of the Interior and Safety.

2. Cancer classification

All cancer cases had been registered in accordance with the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [8]. The range of cancers to be registered and used for the national statistics calculation was limited to records with a behavior code of “/2 (carcinoma in situ)” or “/3 (malignant),” from the morphology (i.e., histology) codes of ICD-O-3, by which a patient was initially enrolled in the KNCI DB. Similar to previous reports, malignant cancer cases and their statistics were mainly assessed in this article. In addition, the supplementary incidence statistics for carcinoma in situ cases were also calculated separately, using 2020 KNCI DB.

For the convenience of classification and reporting, the ICD-O-3 codes were converted to the classification of the International Classification of Diseases, 10th edition (ICD-10) [9]. Exceptionally, some hematopoietic diseases (myeloproliferative disorders/myelodysplastic syndromes) are not classified as malignant cancer in ICD-10 classification, therefore their ICD-O-3 codes were used without any conversion. For mortality data, causes of death were coded according to the ICD-10.

We adopted cancer classifications with 24 and 61 types; the former was a modified classification based on the GLOBOCAN cancer dictionary [10], and the latter was the taxonomy used in “Cancer Incidence in Five Continents” [11], and both of them were provided by the International Association of Cancer Registries. In this article, cancer classification with 24 types of cancer was used for description. The summary staging system developed under the Surveillance, Epidemiology, and End Results (SEER) program (i.e., SEER summary staging) [12] was used to categorize the extent of tumor invasion or metastasis.

3. Statistical analyses

Incidence, mortality, and prevalence rates were expressed as crude rates (CRs) or age-standardized rates (ASRs) per 100,000 people. The CR was defined as the total number of newly diagnosed (for incidence) or deceased (for mortality) cases in a year divided by the mid-year population. The ASR was defined as the weighted average of the age-specific rates in which the weights represent the proportions of people in the corresponding age groups in a standard population [13]. ASRs were standardized using Segi’s world standard population [14]. The cumulative risk of developing cancer from birth to life expectancy during 2020 in Korea were also assessed, assuming no other cause of death (i.e., by simply calculating the sum of the age-specific cancer rates from birth to life expectancy), as follows [13]:

Cumulative risk of developing cancer from birth to life expectancy=100×(1-e-cumulative rate100)

Trends in ASRs were estimated using Joinpoint regression, with a maximum number of two joinpoints. The results were summarized as annual percentage changes with the best model fit, based on a linear model for the natural log-transformed ASRs.

The survival rate of cancer patients, diagnosed between 1993 and 2020, was calculated based on the results of follow-up until December 31, 2021. The 5-year relative survival rate was defined as the ratio of observed survival of cancer patients to expected survival in the general population, adjusting the effects of other causes of death using the standard population life table provided by Statistics Korea [2]. Relative survival rates were estimated using the Ederer II method [15] with some minor corrections, based on an algorithm devised by Paul Dickman [16]. Trends in 5-year relative survival rates were evaluated as percent differences in survival rates between 1993–1995 and 2016–2020.

Prevalent cases were defined as the number of cancer patients alive on January 1, 2021 among all the patients diagnosed with cancer between 1999 and 2020. p < 0.05 was considered statistically significant. SEER*Stat, Joinpoint 4.7.0.0 (National Cancer Institute, Bethesda, MD), and SAS ver. 9.4 (SAS Institute Inc., Cary, NC) were used for statistical analyses.

Results

1. Incidence

The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, a total of 247,952 people were newly diagnosed with cancer in Korea, of which 52.7% (130,618 cases) were men and 47.3% (117,334 cases) were women (Table 1). The five most diagnosed cancers in Korea were thyroid, lung, colorectal, stomach, and breast cancers; in men, lung and stomach cancers were followed by prostate, colorectal, and liver cancers, whereas breast and thyroid cancers were followed by colorectal, lung, and stomach cancers in women. These top five cancers in each sex accounted for 62.8% and 64.8% of all cancer cases in men and women, respectively. Among the five most diagnosed cancers, the decrease in new cancer diagnosis in 2020 compared to 2019 was the largest for stomach cancer (3,058 cases, −10.3%), followed by thyroid cancer (1,827 cases, −5.9%), and colorectal cancer (1,549 cases, −5.3%). Thyroid cancer was the most frequent cancer from 2010 to 2014: its ranking fell after the debate on overdiagnosis in 2014, but recently rose again and regained the first rank since 2019. Table 2 provides the CRs and ASRs of cancer incidence in 2020. The CR and ASR of all cancer incidence were 482.9 per 100,000 (510.1 for men and 455.8 for women) and 262.2 per 100,000 (279.1 for men and 257.3 for women), respectively. The difference bet-ween CR and ASR implies that majority of cancer patients in Korea belong to the elderly, as opposed to the world’s standard population, which has a higher proportion of young people. The overall lifetime probability of being diagnosed with any cancer was 36.9%, under the condition that one survives to the age that matches the life expectancy of the Korean population. That probability was higher in men (39.0%) than in women (33.9%) (data not shown).

Cancer incidence, deaths and prevalence by sex in Korea, 2020

Crude and age-standardized cancer incidence rates by sex in Korea, 2020

There were marked differences in age-specific incidence rates (Fig. 1). In the childhood population (0–14 years), leukemia, non-Hodgkin lymphoma, and brain and central nervous system (CNS) cancer were the top three cancers in both sexes, accounting for 30.5%, 15.2%, and 12.9% of all cancer cases diagnosed in this age group, respectively. Thyroid cancer was the most common cancer in both sexes among the adolescent and young adult populations (15–34 years), accounting for 52.3% of all cancers diagnosed. The most common cancers in that age group, excluding thyroid cancer, were colorectal cancer and leukemia in men, and breast and cervical cancer in women. In the 35–64-year age group, men were most commonly diagnosed with stomach, colorectal, liver, and thyroid cancers (collectively accounting for 51.5%), while breast and thyroid cancers were the most common in women (collectively accounting for 54.6%). For those aged 65 years and above, lung and prostate cancers were the most common in men, while colorectal and lung cancers were the most common in women. Most cancers have shown to increase in incidence with age; the exceptions were thyroid cancer in both sexes and breast cancer in women, which showed the highest incidence in those in their 30–40s and 40–50s age groups, respectively (Fig. 2).

Fig. 1

The five common sites of cancer incidence by age group and sex in Korea, 2020. (A) Men. (B) Women. Numbers in the graph are age-specific incidence rates per 100,000. CNS, central nervous system.

Fig. 2

Age-specific incidence rates of common cancers for 2020 in Korea. (A) Men. (B) Women.

2. Mortality

Since the causes-of-death statistics were published in 1983, cancer has been the number one cause of death in Korea. As of 2020, a total of 82,204 people (61.8% men and 38.2% women) died of cancer, accounting for 27.0% of all deaths in Korea (Tables 1 and 3). The overall CR for cancer deaths was 160.1 per 100,000, and the rate was approximately 1.6 times higher for men than for women (Table 4). Lung cancer was the leading cause of cancer death in both sexes (CR, 54.0 per 100,000 in men and 18.8 per 100,000 in women), followed by liver and colorectal cancers in men, and colorectal and pancreatic cancers in women. When stratified according to the age at the time of death, the most common causes of cancer mortality in both sexes were as follows: leukemia in their 10s and 20s, breast cancer in their 30s, liver cancer in their 40s and 50s, and lung cancer among those 60 years old or older (data not shown).

The top 10 leading causes of death in Korea, 2020

Crude and age-standardized cancer mortality rates by sex in Korea, 2020

3. Trends in cancer incidence and mortality

Changes in cancer incidence rates from 1999 to 2020 and mortality rates from 1983 to 2020 are depicted in Fig. 3. Compared to 1999, cancer incidence rates increased about 23.6% and mortality rates decreased about 39.3%, in 2020 (Table 5). The overall cancer incidence rates increased by approximately 3.3% per year until 2012, followed by a decline until 2015 with an annual decrease of 5.0%, and thereafter showed nonsignificant changes. In contrast, cancer mortality rates demonstrated nonsignificant changes until 2002, and decreased thereafter with an annual decrease of 2.7% until 2013, and a further decrease of 3.3% per year until 2020. These trends were observed similarly in both men and women, although the slopes of change were much more pronounced in women for incidence, and in men for mortality rates (S1 and S2 Tables).

Fig. 3

Annual age-standardized cancer incidence and death rates by sex for all sites from 1983 to 2020 in Korea. Age standardization was based on the Segi’s world standard population.

Trends in cancer incidence and mortality rates from 1999 to 2020 in Korea, both sexes

Since 1999, breast, pancreas, kidney, and hematologic (leukemia and lymphoma) cancers, and that of some male or female reproductive organs (ovary, corpus uteri, prostate, and testis) have been continuously increasing. In both sexes combined, breast (especially for women) and kidney cancers displayed initial rapid increases and then lessened increases after 2008 and 2009, respectively. Prostate cancer demonstrated distinguished increase until 2009, followed by nonsignificant trend until 2015, and regained increasing trend thereafter. The remaining cancers with increasing trend revealed steady increases throughout the entire period. On the other hand, the incidences of colorectal and bladder cancers demonstrated increasing trends that have recently reversed significantly, with decreases starting in 2011 and 2004, respectively. In contrast, stomach and liver cancers demonstrated initial moderate decreasing trends until 2011 and 2010, respectively, followed by more rapid decreases thereafter; and cervical cancer showed marked decrease until 2007, however it showed lessened decrease thereafter until now. Lastly, the incidence of thyroid cancer increased significantly between 1999 and 2011, decreased significantly between 2011 and 2016, and increased again from 2016 without statistical significance (Table 5). These trends were observed similarly in both men and women, except for breast cancer in men and bladder cancer in women that revealed partially different results of trends from those described above. In men, decreasing trend of stomach, lung, and liver cancer throughout the period and colorectal cancer since 2011 were significant while prostate and kidney cancer had an increasing trend. In women, stomach, colorectal, liver, and cervix cancer had decreasing trend while breast and lung cancer revealed an increasing trend. The characteristic trend of thyroid cancer which changed rapidly in a short period of time, was more pronounced in women than in men (Fig. 4, S1 and S2 Tables).

Fig. 4

Trends in age-standardized incidences of selected cancers by sex from 1999 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.

The ASRs for mortality in most cancers have shown decreasing trends in Korea. Stomach cancer revealed continuous decreasing trends throughout the entire observed period for mortality, with more pronounced decreasing slopes in more recent periods. Liver and lung cancer mortality rates began to decrease in 2002 and 2001, respectively, followed by further rapid decreases starting in 2014 and 2013, respectively. On the other hand, the mortality rates of colorectal, cervical, and thyroid cancers initially increased significantly until 2003; since then, the mortality rate from these cancers significantly decreased (Table 5). These trends were observed similarly in both sexes. However, breast cancer in women displayed significantly increasing mortality trends throughout the entire observed period, with less increasing trend after 2005 (Fig. 5, S1 and S2 Tables).

Fig. 5

Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on the Segi’s world standard population.

4. Survival rates

Over the past two decades, when cancer survival statistics have been compiled, the relative survival rates of cancer patients have increased significantly and steadily. The 5-year relative survival rates for all patients diagnosed with cancer in the recent 5 years, from 2016 to 2020 were 71.5% in both sexes; 65.5% in men and 77.8% in women (Table 6). The temporal increasing trends in survival rates, from 42.9% in 1993–1995 to 71.5% in 2016–2020, were maintained even after excluding thyroid cancer (from 41.2% in 1993–1995 to 67.3% in 2016–2020), which has an excellent prognosis with a 5-year relative survival rate of 100%.

Trends in the 5-year relative survival rates (%) by sex and year of diagnosis from 1993 to 2020 in Korea

After thyroid cancer, survival rates were the highest for testis and prostate cancers in men (96.5% and 95.2%, respectively) and breast cancer in women (93.8%). On the contrary, the survival rates were the lowest for cancers of the pancreas (15.2%), and gallbladder plus other and unspecified parts of the biliary tract (29.0%) in both sexes. Stomach cancer (both sexes), prostate cancer (men), lung cancer, and leukemia (women) were associated with outstanding improvements in survival rates over the observed period. In contrast, advances have been slow for cancers of the brain and CNS, pancreas in both sexes.

In terms of stage distribution at diagnosis and recent survival rates according to the SEER summary stage in each cancer, Fig. 6 shows the top 10 most common cancers for each sex in 2020. In men, kidney, stomach, and bladder cancers revealed the highest proportions of patients who were diagnosed at the localized stage (72.9%, 64.7%, and 71.9%, respectively), accompanied by the 5-year survival rates of 98.4%, 98.2%, and 86.2%, respectively. In contrast, lung and pancreatic cancers demonstrated the highest proportions of patients diagnosed at the distant metastatic stage, which approximated to 50%, with corresponding 5-year survival rates of 8.8% and 2.5%, respectively. In women, 59.1%, 72.1%, and 63.5% of breast, uterine corpus, and stomach cancers, respectively, were diagnosed at the localized stage, with 5-year survival rates of 99.0%, 96.8%, and 96.0%, respectively. However, more than 40% of lung and pancreatic cancers were diagnosed at the distant metastatic stage, with 5-year survival rates of 17.8% and 2.4%, respectively.

Fig. 6

Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2016–2020. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results (SEER) stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

5. Prevalence rates

The total prevalent cancer cases in 2020 (identified as survivor at the time of January 1, 2021) were 2,276,792, surpassing 2 million since 2018 (Table 1). It suggested that one in 23 people (4.4% of the entire Korean population; 3.9% of men and 5.0% of women) has a history of being diagnosed with cancer. Of these, 1,090,322 (47.9% of all prevalent cases) were aged ≥ 65 years, indicating that one in seven people in that age group (16.8% of, or one in six, men and 10.8% of, or one in nine, women) would have experienced cancer (data not shown).

Table 7 provides the CRs and ASRs of prevalence for all cancers combined and for specific cancers. In total, the cancer prevalence rate for 2020 in Korea was 4,433.9 per 100,000 people. Thyroid cancer had the highest prevalence (CR, 953.6 per 100,000; 357.5 per 100,000 for men and 1,546.6 per 100,000 for women), followed by stomach cancer (CR, 643.1 per 100,000) and colorectal cancer (CR, 569.8 per 100,000). Prostate cancer in men and breast cancer in women revealed the highest prevalence rates (CR, 470.3 and 1,083.6 per 100,000, respectively).

Crude and age-standardized rates of cancer prevalence by sex on January 1, 2020 in Korea

The number of prevalent cases for common cancers, according to the time since cancer diagnosis, are described in Fig. 7. In total, 1,368,140 (60.1% of all prevalent cases) had survived > 5 years after cancer diagnosis, majority of them being survivors of thyroid, stomach, colorectal, and breast cancers. Another 487,192 (21.4% of all prevalent cases) have been alive 2–5 years after their cancer diagnosis, in which period they need regular follow-up; and the rest were 421,460 (18.5% of all prevalent cases) for whom it had been < 2 years since their cancer diagnosis, in which period they still need active cancer treatment.

Fig. 7

Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2021 among all cancer patients diagnosed between 1999 and 2020.

6. Carcinoma in situ incidence

A summary of carcinoma in situ cases in 2020 is provided as a Supplementary Material (S3S6 Tables, S7S9 Figs.).

Conclusion

Compared to 2019, the number of new cancer diagnoses in 2020 decreased due to the impact of the COVID-19 pandemic. Except for 2020, the number of new cancer patients in Korea has been increasing since 2015, but the ASRs of incidence did not reveal a significant change. During the past decade, the incidence of stomach, colorectal, liver, and cervical cancer has been declining while that of prostate and breast cancer have been on the rise since 1999. Thyroid cancer, which has decreased since 2012, has shown an increasing trend since 2015. The 5-year relative survival rate of cancer patients diagnosed in the past 5 years was 71.5%, which is steadily improving. Since 2018, the number of cancer survivors has exceeded 2 million, of which 60.1% are those who survived over 5 years. As the number of newly diagnosed cancer patients, cancer survival rates and cancer prevalence continue to increase, national cancer control strategies must be planned and implemented to keep pace with these changing cancer statistics. In addition, the impact of the COVID-19 pandemic on cancer diagnosis and treatment should be evaluated in further studies.

Notes

Author Contributions

Conceived and designed the analysis: Jung KW.

Collected the data: Jung KW, Regional Cancer Registry Committee.

Contributed data or analysis tools: Kang MJ, Jung KW, Kong HJ, Kim HJ, Park EH, Yun EH.

Performed the analysis: Bang SH, Choi SH

Wrote the paper: Kang MJ, Jung KW.

Interpretation and review: Jung KW, Kong HJ.

Review and comment: Im JS, Seo HG.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

Special thanks to the tumor registrars (health information managers) of the Korea Central Cancer Registry (KCCR)-affiliated and non-KCCR-affiliated hospitals for data collection, abstracting, and coding. Additionally, we acknowledge the cooperation of the National Health Insurance Service and Statistics Korea for data support. This work was supported by the Health Promotion Fund of the Ministry of Health & Welfare (No. 2260020) and a research grant (No. 2211110) from the National Cancer Center, Republic of Korea.

References

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today [Internet] Lyon: International Agency for Research on Cancer; 2020. [cited 2023 Feb 6]. Available from: https://gco.iarc.fr/today.
2. Statistics Korea [Internet] Daejeon: Statistics Korea; 2021. [cited 2023 Feb 6]. Available from: http://kosis.kr.
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.
4. Lee K, Lee YY, Suh M, Jun JK, Park B, Kim Y, et al. Impact of COVID-19 on cancer screening in South Korea. Sci Rep 2022;12:11380.
5. Teglia F, Angelini M, Astolfi L, Casolari G, Boffetta P. Global association of COVID-19 pandemic measures with cancer screening: a systematic review and meta-analysis. JAMA Oncol 2022;8:1287–93.
6. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat 2005;37:325–31.
7. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi 1998;45:1011–7.
8. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology 3rd edth ed. 1st rev. Geneva: World Health Organization; 2013.
9. World Health Organization. International statistical classification of diseases and related health problems 10th rev. th ed. Geneva: World Health Organization; 1994.
10. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today – data and methods [Internet] Lyon: International Agency for Research on Cancer; 2020. [cited 2023 Feb 6]. Available from: https://gco.iarc.fr/today/data-sources-methods.
11. Cancer incidence in five continents, XI Chapter 3. Classification and coding [Internet] Lyon: International Agency for Research on Cancer; 2017. [cited 2023 Feb 6]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter3.aspx.
12. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual 2000: codes and coding instructions. National Cancer Institute, NIH Pub No. 01-4969 Bethesda, MD: National Cancer Institute; 2001.
13. Cancer incidence in five continents, XI Chapter 7. Age standardization [Internet] Lyon: International Agency for Research on Cancer; 2017. [cited 2023 Feb 6]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter7.aspx.
14. Segi M. Cancer mortality for selected sites in 24 countries 1950–1957 Sendai: Tohoku University School of Medicine; 1960.
15. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No 10 Bethesda, MD: National Cancer Institute; 1959.
16. Paul Dickman [Internet] Stockholm: PaulDickman.com; 2016. [cited 2023 Feb 6]. Available from: http://www.pauldickman.com.

Article information Continued

Funded by : Health Promotion Fund of the Ministry of Health & Welfare
Award ID : 2260020
Award ID : 2211110
Funded by : National Cancer Center, Republic of Korea
Funding : This work was supported by the Health Promotion Fund of the Ministry of Health & Welfare (No. 2260020) and a research grant (No. 2211110) from the National Cancer Center, Republic of Korea.

Fig. 1

The five common sites of cancer incidence by age group and sex in Korea, 2020. (A) Men. (B) Women. Numbers in the graph are age-specific incidence rates per 100,000. CNS, central nervous system.

Fig. 2

Age-specific incidence rates of common cancers for 2020 in Korea. (A) Men. (B) Women.

Fig. 3

Annual age-standardized cancer incidence and death rates by sex for all sites from 1983 to 2020 in Korea. Age standardization was based on the Segi’s world standard population.

Fig. 4

Trends in age-standardized incidences of selected cancers by sex from 1999 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.

Fig. 5

Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on the Segi’s world standard population.

Fig. 6

Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2016–2020. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results (SEER) stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

Fig. 7

Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2021 among all cancer patients diagnosed between 1999 and 2020.

Table 1

Cancer incidence, deaths and prevalence by sex in Korea, 2020

Site/Type New cases Deaths Prevalent casesa)



Both sexes Men Women Both sexes Men Women Both sexes Men Women
All sites 247,952 130,618 117,334 82,204 50,817 31,387 2,276,792 998,948 1,277,844

Lip, oral cavity, and pharynx 4,064 2,892 1,172 1,283 972 311 31,447 20,948 10,499

Esophagus 2,748 2,451 297 1,564 1,404 160 12,684 11,274 1,410

Stomach 26,662 17,869 8,793 7,510 4,807 2,703 330,217 217,881 112,336

Colon and rectum 27,877 16,485 11,392 8,869 5,029 3,840 292,586 173,285 119,301

Liver 15,152 11,150 4,002 10,565 7,812 2,753 77,958 58,239 19,719

Gallbladderb) 7,452 4,012 3,440 5,192 2,784 2,408 26,685 13,770 12,915

Pancreas 8,414 4,324 4,090 6,775 3,452 3,323 16,415 8,293 8,122

Larynx 1,203 1,141 62 321 310 11 12,251 11,524 727

Lung 28,949 19,657 9,292 18,673 13,824 4,849 111,208 66,240 44,968

Breast 24,923 117 24,806 2,745 20 2,725 279,965 1,012 278,953

Cervix uteri 2,998 - 2,998 810 - 810 60,467 - 60,467

Corpus uteri 3,492 - 3,492 378 - 378 33,785 - 33,785

Ovary 2,947 - 2,947 1,369 - 1,369 25,683 - 25,683

Prostate 16,815 16,815 - 2,194 2,194 - 120,423 120,423 -

Testis 361 361 - 14 14 - 4,385 4,385 -

Kidney 5,946 4,135 1,811 1,076 764 312 54,652 36,986 17,666

Bladder 4,753 3,826 927 1,593 1,235 358 41,835 34,085 7,750

Brain and CNS 1,970 1,056 914 1,437 784 653 13,411 6,888 6,523

Thyroid 29,180 7,458 21,722 365 128 237 489,688 91,546 398,142

Hodgkin lymphoma 323 214 109 48 30 18 3,657 2,255 1,402

Non-Hodgkin lymphoma 5,636 3,248 2,388 1,926 1,106 820 40,853 23,163 17,690

Multiple myeloma 1,747 961 786 976 514 462 8,307 4,381 3,926

Leukemia 3,605 2,020 1,585 1,825 1,048 777 27,157 15,045 12,112

Other and ill-defined 20,735 10,426 10,309 4,696 2,586 2,110 161,073 77,325 83,748

CNS, central nervous system.

a)

Limited-duration prevalent cases on January 1, 2020. These are patients who were diagnosed between January 1, 1999 and December 31, 2020 and who were alive on January 1, 2021. Multiple primary cancer cases were counted multiple times,

b)

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2

Crude and age-standardized cancer incidence rates by sex in Korea, 2020

Site/Type Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)


Both sexes Men Women Both sexes Men Women
All sites 482.9 510.1 455.8 262.2 279.1 257.3

Lip, oral cavity, and pharynx 7.9 11.3 4.6 4.4 6.4 2.6

Esophagus 5.4 9.6 1.2 2.6 4.9 0.5

Stomach 51.9 69.8 34.2 25.7 36.9 15.9

Colon and rectum 54.3 64.4 44.3 27.1 34.8 20.2

Liver 29.5 43.5 15.5 14.5 23.2 6.7

Gallbladderb) 14.5 15.7 13.4 6.2 7.7 4.9

Pancreas 16.4 16.9 15.9 7.6 8.7 6.7

Larynx 2.3 4.5 0.2 1.1 2.3 0.1

Lung 56.4 76.8 36.1 25.8 38.5 15.9

Breast 48.5 0.5 96.4 30.1 0.2 59.9

Cervix uteri 5.8 - 11.6 3.7 - 7.3

Corpus uteri 6.8 - 13.6 4.2 - 8.4

Ovary 5.7 - 11.4 3.5 - 7.0

Prostate 32.7 65.7 - 14.7 32.5 -

Testis 0.7 1.4 - 0.7 1.4 -

Kidney 11.6 16.1 7.0 6.6 9.4 3.9

Bladder 9.3 14.9 3.6 4.1 7.5 1.4

Brain and CNS 3.8 4.1 3.6 2.8 3.2 2.4

Thyroid 56.8 29.1 84.4 41.3 20.9 62.4

Hodgkin lymphoma 0.6 0.8 0.4 0.5 0.7 0.4

Non-Hodgkin lymphoma 11.0 12.7 9.3 6.6 8.1 5.2

Multiple myeloma 3.4 3.8 3.1 1.6 1.9 1.4

Leukemia 7.0 7.9 6.2 5.4 6.1 4.8

Other and ill-defined 40.4 40.7 40.0 21.4 23.7 19.4

CNS, central nervous system.

a)

Age-adjusted using the Segi’s world standard population,

b)

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3

The top 10 leading causes of death in Korea, 2020

Rank Cause of death No. of deaths Percentage of all deaths Age-standardized death rate per 100,000a)
All causes 304,948 100.0 249.4
1 Cancer 82,204 27.0 69.9
2 Heart disease 32,347 10.6 24.2
3 Cerebrovascular disease 21,860 7.2 16.2
4 Pneumonia 22,257 7.3 14.8
5 Intentional self-harm (suicide) 13,195 4.3 17.9
6 Diabetes mellitus 8,456 2.8 6.3
7 Disease of liver 6,979 2.3 7.1
8 Chronic lower respiratory diseases 5,668 1.9 3.8
9 Hypertensive diseases 6,100 2.0 4.0
10 Transport accidents 3,947 1.3 4.6
Others 101,935 33.4 80.5

Source: Mortality Data, 2020, Statistics Korea [2].

a)

Age-adjusted using the Segi’s world standard population.

Table 4

Crude and age-standardized cancer mortality rates by sex in Korea, 2020

Site/Type Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)


Both sexes Men Women Both sexes Men Women
All sites 160.1 198.5 121.9 69.9 99.4 47.8

Lip, oral cavity, and pharynx 2.5 3.8 1.2 1.2 2.0 0.5

Esophagus 3.0 5.5 0.6 1.4 2.7 0.3

Stomach 14.6 18.8 10.5 6.4 9.5 4.1

Colon and rectum 17.3 19.6 14.9 7.2 9.9 5.2

Liver 20.6 30.5 10.7 9.4 15.7 3.9

Gallbladderb) 10.1 10.9 9.4 4.0 5.2 3.1

Pancreas 13.2 13.5 12.9 5.7 6.8 4.7

Larynx 0.6 1.2 0.0 0.3 0.6 0.0

Lung 36.4 54.0 18.8 14.9 25.9 6.6

Breast 5.3 0.1 10.6 2.9 0.0 5.6

Cervix uteri 1.6 - 3.1 0.8 - 1.5

Corpus uteri 0.7 - 1.5 0.4 - 0.7

Ovary 2.7 - 5.3 1.3 - 2.6

Prostate 4.3 8.6 - 1.5 4.0 -

Testis 0.0 0.1 - 0.0 0.0 -

Kidney 2.1 3.0 1.2 0.9 1.5 0.4

Bladder 3.1 4.8 1.4 1.2 2.3 0.4

Brain and CNS 2.8 3.1 2.5 1.6 1.9 1.3

Thyroid 0.7 0.5 0.9 0.3 0.2 0.3

Hodgkin lymphoma 0.1 0.1 0.1 0.0 0.1 0.0

Non-Hodgkin lymphoma 3.8 4.3 3.2 1.7 2.3 1.2

Multiple myeloma 1.9 2.0 1.8 0.8 1.0 0.6

Leukemia 3.6 4.1 3.0 1.9 2.4 1.5

Other and ill-defined 9.1 10.1 8.2 4.2 5.5 3.2

CNS, central nervous system.

a)

Age-adjusted using the Segi’s world standard population,

b)

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 5

Trends in cancer incidence and mortality rates from 1999 to 2020 in Korea, both sexes

Site/Type Incidence Mortality


1999 2020 Trend 1 Trend 2 Trend 3 1999 2020 Trend 1 Trend 2 Trend 3






Years APC Years APC Years APC Years APC Years APC Years APC
All sites 212.1 262.2 1999–2012 3.3a) 2012–2015 −5.0a) 2015–2020 0.3 115.1 69.9 1999–2002 0.9 2002–2013 −2.7a) 2013–2020 −3.3a)

Lip, oral cavity, and pharynx 3.6 4.4 1999–2020 0.7a) - - - - 1.1 1.2 1999–2020 −1.8a) - - - -

Esophagus 4.1 2.6 1999–2020 −2.0a) - - - - 3.1 1.4 1999–2020 −4.3a) - - - -

Stomach 43.6 25.7 1999–2011 −0.2 2011–2020 −4.8a) - - 23.9 6.4 1999–2002 −2.5a) 2002–2010 −6.4a) 2010–2020 −7.2a)

Colon and rectum 20.5 27.1 1999–2006 7.3a) 2006–2011 2.9a) 2011–2020 −3.8a) 7.8 7.2 1999–2003 6.5a) 2003–2012 −0.5a) 2012–2020 −3.6a)

Liver 27.9 14.5 1999–2010 −1.7a) 2010–2020 −4.3a) - - 20.6 9.4 1999–2002 0.6 2002–2014 −3.7a) 2014–2020 −5.9a)

Gallbladderb) 6.5 6.2 1999–2004 1.4 2004–2018 −0.3 2018–2020 −3.6 5.2 4.0 1999–2001 7.7 2001–2013 −2.9a) 2013–2020 −0.7

Pancreas 5.6 7.6 1999–2020 1.6a) - - - - 5.5 5.7 1999–2020 0.1 - - - -

Larynx 2.4 1.1 1999–2020 −3.5a) - - - - 1.6 0.3 1999–2005 −8.1a) 2005–2008 −15.5a) 2008–2020 −7.2a)

Lung 28.5 25.8 1999–2020 −0.3a) - - - - 22.5 14.9 1999–2001 3.6 2001–2013 −1.9a) 2013–2020 −3.6a)

Breast 11.0 30.1 1999–2008 6.3a) 2008–2020 4.1a) - - 2.3 2.9 1999–2004 2.9a) 2004–2020 0.8a) - -

Cervix uteri 8.6 3.7 1999–2007 −4.6a) 2007–2020 −3.2a) - - 1.4 0.8 1999–2003 10.1a) 2003–2008 −7.1a) 2008–2020 −4.2a)

Corpus uteri 1.4 4.2 1999–2020 5.1a) - - - - 0.1 0.4 1999–2003 36.1a) 2003–2020 2.3a) - -

Ovary 2.7 3.5 1999–2020 1.7a) - - - - 0.9 1.3 1999–2020 0.6a) - - -

Prostate 3.1 14.7 1999–2009 14.8a) 2009–2015 1 2015–2020 5.6a) 0.9 1.5 1999–2002 15.0a) 2002–2010 1.9a) 2010–2020 −1.1a)

Testis 0.3 0.7 1999–2020 4.8a) - - - - 0.0 0.0 1999–2020 −2.4a) - - - -

Kidney 3.0 6.6 1999–2009 6.4a) 2009–2020 2.2a) - - 1.1 0.9 1999–2016 −0.2 2016–2020 −4.7a) - -

Bladder 4.7 4.1 1999–2004 1.9 2004–2020 −1.1a) - - 1.3 1.2 1999–2002 9.3a) 2002–2005 −6.0 2005–2020 −1.5a)

Brain and CNS 2.9 2.8 1999–2020 0.1 - - - - 1.9 1.6 1999–2003 4.1a) 2003–2008 −4.3a) 2008–2020 −0.8a)

Thyroid 6.5 41.3 1999–2011 22.4a) 2011–2016 −12.1a) 2016–2020 4.5 0.4 0.3 1999–2003 7.4a) 2003–2020 −4.5a) - -

Hodgkin lymphoma 0.3 0.5 1999–2011 4.9a) 2011–2020 1.6 - - 0.0 0.0 1999–2004 24.7a) 2004–2020 −2.6a) - -

Non-Hodgkin lymphoma 4.3 6.6 1999–2020 2.3a) - - - - 2.1 1.7 1999–2020 −1.1a) - - - -

Multiple myeloma 1.0 1.6 1999–2013 3.7a) 2013–2020 0.3 - - 0.6 0.8 1999–2003 12.8a) 2003–2016 0.8 2016–2020 −6.0a)

Leukemia 4.7 5.4 1999–2020 0.9a) - - - - 2.9 1.9 1999–2020 −1.9a) - - - -

Other and ill-defined 15.0 21.4 1999–2018 2.3a) 2018–2020 −2.1 - - 7.8 4.2 1999–2020 −2.7a) - - - -

APC, annual percentage change; CNS, central nervous system. APC was calculated using age-standardized incidence data based on the Segi’s world standard population.

a)

Significantly different from zero (p < 0.05),

b)

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 6

Trends in the 5-year relative survival rates (%) by sex and year of diagnosis from 1993 to 2020 in Korea

Site/Type Both sexes Men Women



1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2016–2020 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2016–2020 Changea) 1993–1995 1996–2000 2001–2005 2006–2010 2011–2015 2016–2020 Changea)
All sites 42.9 45.2 54.1 65.5 70.7 71.5 28.6 33.2 36.4 45.6 56.9 63.1 65.5 32.3 55.2 56.4 64.3 74.4 78.3 77.8 22.6

All sites excluding thyroid 41.2 43.4 50.9 59.1 64.3 67.3 26.1 32.7 35.9 44.7 54.6 60.4 63.4 30.7 52.6 53.5 59.1 65.0 69.4 72.2 19.6

Lip, oral cavity, and pharynx 42.2 47.4 54.5 61.1 65.5 69.4 27.2 36.6 41.7 49.7 56.9 61.8 66.7 30.1 59.4 64.5 68.1 72.1 74.5 75.8 16.5

Esophagus 14.0 15.7 21.6 30.0 36.6 42.2 28.2 13.0 14.7 20.8 29.4 36.2 41.8 28.7 25.0 25.9 29.8 37.3 39.6 45.6 20.6

Stomach 43.9 47.3 58.0 68.4 75.9 78.0 34.1 44.0 47.6 58.7 69.1 76.8 78.9 35.0 43.7 46.8 56.6 67.0 74.0 76.0 32.3

Colon and rectum 56.2 58.9 66.9 73.9 76.1 74.3 18.1 56.7 59.8 68.8 75.8 77.8 75.6 19.0 55.7 57.7 64.5 71.1 73.6 72.3 16.7

Liver 11.8 14.1 20.5 28.3 34.4 38.7 26.9 10.8 13.8 20.4 28.3 35.0 39.1 28.2 15.1 15.1 20.9 28.3 32.8 37.6 22.6

Gallbladderb) 18.7 20.7 23.1 26.9 28.8 29.0 10.4 18.0 21.1 23.5 27.8 29.5 29.8 11.7 19.3 20.3 22.7 26.0 28.0 28.2 8.9

Pancreas 10.6 8.7 8.4 8.6 10.9 15.2 4.6 10.0 8.3 8.4 8.3 10.3 14.2 4.2 11.5 9.3 8.4 8.9 11.6 16.2 4.7

Larynx 61.6 63.3 66.5 73.2 75.3 80.0 18.3 62.2 63.7 67.1 73.5 75.7 80.1 17.9 56.3 58.9 58.7 68.0 69.4 78.3 22.0

Lung 12.5 13.7 16.6 20.3 27.6 36.8 24.3 11.6 12.4 15.3 18.0 23.4 30.6 19.0 15.8 17.5 20.2 26.0 37.4 50.3 34.4

Breast 79.2 83.6 88.7 91.2 92.8 93.8 14.5 77.1 84.3 87.5 89.9 90.8 92.5 15.4 79.3 83.6 88.7 91.2 92.8 93.8 14.5

Cervix uteri 78.3 80.3 81.5 80.7 80.3 80.1 1.7 - - - - - - - 78.3 80.3 81.5 80.7 80.3 80.1 1.7

Corpus uteri 82.9 82.0 84.8 86.5 87.7 89.3 6.4 - - - - - - - 82.9 82.0 84.8 86.5 87.7 89.3 6.4

Ovary 60.1 59.4 61.7 61.3 64.9 64.7 4.6 - - - - - - - 60.1 59.4 61.7 61.3 64.9 64.7 4.6

Prostate 59.1 69.4 81.0 92.0 94.2 95.2 36.1 59.1 69.4 81.0 92.0 94.2 95.2 36.1 - - - - - - -

Testis 87.4 90.4 90.7 93.2 94.9 96.5 9.0 87.4 90.4 90.7 93.2 94.9 96.5 9.0 - - - - - - -

Kidney 64.2 67.0 73.7 78.6 82.6 85.7 21.4 63.4 65.3 73.0 78.5 82.2 85.8 22.4 65.8 70.3 74.9 78.9 83.4 85.3 19.4

Bladder 70.7 73.6 76.0 77.3 76.5 76.5 5.8 71.6 75.1 77.8 79.3 78.5 78.6 7.0 67.2 67.2 69.1 69.2 68.5 68.4 1.2

Brain and CNS 40.4 39.9 41.1 42.9 41.8 40.5 0.1 39.0 38.7 40.4 41.4 40.4 38.4 −0.6 42.3 41.4 41.9 44.7 43.4 43.0 0.7

Thyroid 94.5 95.0 98.4 100.0 100.2 100.0 5.5 87.9 89.7 96.0 100.2 100.6 100.3 12.4 95.7 96.0 98.7 99.9 100.1 100.0 4.3

Hodgkin lymphoma 70.2 71.9 76.7 81.1 82.3 87.1 16.9 69.4 69.3 74.7 80.8 81.8 87.1 17.6 71.5 77.3 80.7 81.6 83.3 87.2 15.7

Non-Hodgkin lymphoma 48.3 51.1 56.0 59.4 62.9 65.4 17.1 46.8 49.6 55.0 59.2 62.9 65.9 19.1 50.7 53.3 57.5 59.7 62.8 64.8 14.1

Multiple myeloma 23.7 21.0 29.7 35.0 41.6 50.7 27.0 23.2 19.1 29.9 35.2 41.2 51.4 28.2 24.1 23.2 29.5 34.7 42.1 49.8 25.7

Leukemia 27.5 34.3 42.0 47.7 52.0 55.2 27.6 27.3 33.3 41.8 46.9 52.2 54.8 27.5 27.9 35.5 42.1 48.7 51.7 55.6 27.7

Other and ill-defined 44.5 48.4 57.9 67.7 72.8 76.4 31.9 39.6 44.7 54.1 63.8 69.4 73.4 33.8 50.1 52.7 62.0 71.6 76.2 79.3 29.2

CNS, central nervous system.

a)

Absolute percentage change in 5-year relative survival from 1993 to 1995 and 2016 to 2020,

b)

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 7

Crude and age-standardized rates of cancer prevalence by sex on January 1, 2020 in Korea

Site/Type Crude prevalence rate per 100,000a) Age-standardized prevalence rate per 100,000b)


Both sexes Men Women Both sexes Men Women
All sites 4,433.9 3,901.2 4,963.8 2,373.6 2,121.4 2,708.5

Lip, oral cavity, and pharynx 61.2 81.8 40.8 33.4 45.8 22.3

Esophagus 24.7 44.0 5.5 11.4 22.1 2.4

Stomach 643.1 850.9 436.4 304.5 436.8 194.1

Colon and rectum 569.8 676.7 463.4 267.5 350.3 199.5

Liver 151.8 227.4 76.6 77.2 122.3 36.0

Gallbladderc) 52.0 53.8 50.2 22.9 27.0 19.7

Pancreas 32.0 32.4 31.6 16.3 17.4 15.6

Larynx 23.9 45.0 2.8 10.9 22.6 1.2

Lung 216.6 258.7 174.7 101.5 131.0 78.8

Breast 545.2 4.0 1,083.6 307.6 2.1 606.2

Cervix uteri 117.8 - 234.9 65.2 - 128.0

Corpus uteri 65.8 - 131.2 37.1 - 73.2

Ovary 50.0 - 99.8 30.8 - 61.4

Prostate 234.5 470.3 - 96.5 223.9 -

Testis 8.5 17.1 - 7.6 14.8 -

Kidney 106.4 144.4 68.6 57.9 82.0 35.8

Bladder 81.5 133.1 30.1 35.7 66.5 11.6

Brain and CNS 26.1 26.9 25.3 21.2 22.5 19.9

Thyroid 953.6 357.5 1,546.6 587.8 226.8 947.2

Hodgkin lymphoma 7.1 8.8 5.4 5.7 6.8 4.6

Non-Hodgkin lymphoma 79.6 90.5 68.7 50.5 60.4 41.1

Multiple myeloma 16.2 17.1 15.3 7.9 9.0 7.0

Leukemia 52.9 58.8 47.0 46.0 51.4 40.6

Other and ill-defined 313.7 302.0 325.3 170.4 180.1 162.4

CNS, central nervous system.

a)

Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2020 and who were alive on January 1, 2021. Multiple primary cancer cases were counted multiple times,

b)

Age-adjusted using the Segi’s world standard population,

c)

Includes the gallbladder and other/unspecified parts of the biliary tract.